Abstract
Introduction
Recent evidence indicates that the choice of intravenous fluids may affect outcomes in critically ill patients.
Methods
We recorded the administration of resuscitation fluids in patients admitted to Australian and New Zealand adult intensive care units (ICUs) for a 24-h period at 6 time points between 2007 and 2013. Changes in patterns of fluid use over this period were determined using regression analyses.
Results
Of the 2825 patients admitted to the 61 ICUs on the 6 study days, 754 (26.7 %) patients received fluid resuscitation. Of those receiving fluid resuscitation, the proportion of patients receiving crystalloid significantly increased from 28.9 % (41/142) in 2007 to 50.5 % (48/95) in 2013 (adjusted odds ratio (OR) 2.93; 95 % confidence intervals (CI) 1.35–6.33; p = 0.006); of these, the proportion of patients receiving buffered salt solutions significantly increased from 4.9 % (7/142) in 2007 to 31.6 % (30/95) in 2013 (OR 7.00; 95 % CI 2.14–22.92; p = 0.001). The use of colloids significantly decreased from 59.9 % (85/142) in 2007 to 42.1 % (40/95) in 2013 (adjusted OR 0.34; 95 % CI 0.16–0.74; p = 0.007) due to a significant decrease in the proportion of patients receiving gelatin; 28.9 % (41/142) to 2.1 % (2/95) (OR 0.10; 95 % CI 0.03–0.29; p ≤ 0.001).
Conclusion
Fluid resuscitation practice in Australia and New Zealand adult ICUs has changed over the 6-year study period. Crystalloid use increased primarily due to an increase in the use of buffered salt solutions while overall the use of colloid has decreased.
Similar content being viewed by others
References
Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D et al (2010) Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 14:R185
SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N et al (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139
Myburgh J, Finfer S, Bellomo R, Billot L, Cass A, Gattas D et al (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911
Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A et al (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134
SAFE Study Investigators (2007) Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 357:874–884
The SAFE Study Investigators (2011) Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 37:86–96
Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M et al (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 10:1412–1421
Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J et al (2012) Assessment of hemodynamic efficacy and safety of 6 % hydroxyethyl starch 130/0.4 vs. 0.9 % NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16:R94
Perel P, Roberts I, Ker K (2013) Colloids versus crystalloids for fluid resuscitation in critically ill patients (review). Cochrane Database System Rev 2:CD000567
Mutter TC, Ruth CA, Dart AB (2013) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 7:CD007594
Haase N, Perner A, Inkeri Hennings L, Siegemund M, Lauridsen B, Wetterslev M et al (2013) Hydroxyethyl starch 130/0.38–0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839
Zarychanski R, Abou-Setta A, Turgeon A, Houston B, McIntyre L, Marshall J et al (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688
Gattas D, Dan A, Myburgh J, Billot L, Lo S, Finfer S et al (2013) Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4) and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacment therapy. Intensive Care Med 39:558–568
Powell-Tuck J, Gosling P, Lobo D, Allison S, Carlson G, Gore M et al (2011) British Consensus Guidelines on intravenous fluid therapy for adult surgical patients (GIFTASUP). http://www.bapen.org.uk/pdfs/bapen_pubs/giftasup.pdf. Accessed 22 May 2015
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
FDA (2005) Safety of albumin administration in critically ill patients. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/BloodSafety/ucm095539.htm. Accessed 22 May 2015
EMA (2013) PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Solutions_for_infusion_containing_hydroxyethyl_starch/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500144448.pdf. Accessed 22 May 2015
FDA (2013) Hydroxyethyl starch solutions: FDA safety communication—boxed warning on increased mortality and severe renal injury and risk of bleeding. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm358349.htm. Accessed 22 May 2015
MHRA (2013) Hydroxyethyl starch (HES) products—increased risk of renal dysfunction and mortality. https://www.gov.uk/drug-device-alerts/drug-alert-hydroxyethyl-starch-hes-products-increased-risk-of-renal-dysfunction-and-mortality. Accessed 22 May 2015
TGA (2013) Hydroxyethyl starch (Voluven and Volulyte) and increased risk of mortality. http://www.tga.gov.au/monitoring-communication/hydroxyethyl-starch-voluven-and-volulyte-and-increased-risk-mortality. Accessed 22 May 2015
FDA (2013) FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm. Accessed 22 May 2015
Yunos NM, Bellomo R, Glassford N, Sutcliffe H, Lam Q, Bailey M (2014) Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis. Intensive Care Med 41:257–264
Yunos N, Bellomo R, Hegarty C, Story D, Ho L, Bailey M (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308:1566–1572
Shaw A, Bagshaw S, Goldstein S et al (2012) Major complications, mortality, and resource utilization after open abdominal surgery: 0.9 % saline compared to plasma-lyte. Ann Surg 255:821–829
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381
Knaus W, Draper E, Wagner D, Zimmerman J (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829
Miletin M, Stewart T, Norton P (2002) Influences on physicians’ choices of intravenous colloids. Intensive Care Med 28:917–924
Schortgen F, Deye N, Brochard L, CRYCO Study Group (2004) Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 30:2222–2229
The FLUID study Investigators (2008) Preference for colloid use in Scandinavian intensive care units. Acta Anaesthesiol Scand 52:750–758
Zhou F, Peng Z, Bishop J, Cove M, Singbartl K, Kellum J (2014) Effects of fluid resuscitation with 0.9 % saline versus a balanced electrolyte solution on acute kidney injury in a rat model of sepsis. Crit Care Med 42:e270–e278
Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D et al (2011) The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med 39:2419–2424
Raghunathan K, Shaw A, Nathanson B, Stürmer T, Brookhart A, Stefan M et al (2014) Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med 42:1585–1591
The National Heart L, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trial Network (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564–2575
Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA (2011) Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39:259–265
Conflicts of interest
The George Institute for Global Health, the institution of NH, CT, MS, SF, PG, LW, and JM, has received unrestricted grants (administered through the University of Sydney) and travel expenses (SF, JM) in relation to the design and conduct of the Crystalloid versus Hydroxyethyl Starch Trial from Fresenius Kabi, and an unrestricted grant (SF) and advisory board fees and travel expenses (JM) from Baxter HealthCare in relation to fluid resuscitation research (2014). NH received a National Health and Medical Research Council of Australia post-graduate scholarship (2012–2014) that has supported part of this work. CT undertakes consulting work for pharmaceutical companies. CT has not personally undertaken work for CSL, Fresenius Kabi or Baxter. BL owns shares in BioCSL. IS has no conflicts of interest. JM is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia.
Author information
Authors and Affiliations
Corresponding author
Additional information
For the George Institute for Global Health and the Australian and New Zealand Intensive Care Society Clinical Trials Group.
Take-home message: Fluid resuscitation in Australian and New Zealand ICUs changed over a 6-year period with an increased use of crystalloids, primarily due to increased use of buffered salt solutions. Albumin is the most commonly used colloid solution, although the overall use of colloids has decreased, associated with a decrease in the use of gelatin solutions and negligible use of HES.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hammond, N.E., Taylor, C., Saxena, M. et al. Resuscitation fluid use in Australian and New Zealand Intensive Care Units between 2007 and 2013. Intensive Care Med 41, 1611–1619 (2015). https://doi.org/10.1007/s00134-015-3878-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-015-3878-y